Literature DB >> 2013426

Plasma beta endorphin in cirrhosis and renal failure.

J R Thornton1, M S Losowsky.   

Abstract

Whether the plasma concentration of beta endorphin was increased in hepatic cirrhosis like that of smaller opioid peptides methionine enkephalin and leucine enkephalin was determined. Its concentration in chronic renal failure was also measured. Plasma beta endorphin was not significantly raised in cirrhotic patients with or without ascites (medians 5.2 pmol/l and 4.7 pmol/l respectively) compared with disease control subjects (4.9 pmol/l) and healthy control subjects (4.9 pmol/l). In contrast, the peptide was increased 2.5 fold (p less than 0.001) in chronic renal failure (12.4 pmol/l) and was found in many of these patients' urine. The data are compatible with the hypothesis that the liver may play an important role in the elimination of opioid peptides of octapeptide size or less but not the larger peptides such as beta endorphin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013426      PMCID: PMC1378840          DOI: 10.1136/gut.32.3.306

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  23 in total

Review 1.  The role of the kidney in the metabolism of plasma proteins.

Authors:  W Strober; T A Waldmann
Journal:  Nephron       Date:  1974       Impact factor: 2.847

2.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

3.  Dynorphin and dynorphin are ligands for the kappa-subtype of opiate receptor.

Authors:  A D Corbett; S J Paterson; A T McKnight; J Magnan; H W Kosterlitz
Journal:  Nature       Date:  1982-09-02       Impact factor: 49.962

4.  Direct isolation of beta-endorphin from plasma by column chromatography.

Authors:  K W Hindmarsh; D A Todd; E John; W G McBride
Journal:  J Chromatogr       Date:  1982-08-13

5.  IgE-mediated 14C-serotonin release from rat mast cells modulated by morphine and endorphins.

Authors:  Y Yamasaki; O Shimamura; A Kizu; M Nakagawa; H Ijichi
Journal:  Life Sci       Date:  1982-08-02       Impact factor: 5.037

6.  beta-Endorphin is a kidney trophic hormone.

Authors:  M K Haddox; D H Russell
Journal:  Life Sci       Date:  1979-08-13       Impact factor: 5.037

7.  Opioid peptides in human plasma: evidence for multiple forms.

Authors:  M R Boarder; E Erdelyi; J D Barchas
Journal:  J Clin Endocrinol Metab       Date:  1982-04       Impact factor: 5.958

8.  Studies on circulating met-enkephalin and beta-endorphin: normal subjects and patients with renal and adrenal disease.

Authors:  R Smith; A Grossman; R Gaillard; V Clement-Jones; S Ratter; J Mallinson; P J Lowry; G M Besser; L H Rees
Journal:  Clin Endocrinol (Oxf)       Date:  1981-09       Impact factor: 3.478

9.  Diurnal rhythm of beta endorphin in normotensive and hypertensive patients: the effect of clonidine.

Authors:  C Farsang; L Vajda; J Kapocsi; Z Malisák; S Alföldi; K Varga; I Juhász; G Kunos
Journal:  J Clin Endocrinol Metab       Date:  1983-04       Impact factor: 5.958

10.  Diurnal rhythm of plasma immunoreactive beta-endorphin and its relationship to sleep stages and plasma rhythms of cortisol and prolactin.

Authors:  R R Dent; C Guilleminault; L H Albert; B I Posner; B M Cox; A Goldstein
Journal:  J Clin Endocrinol Metab       Date:  1981-05       Impact factor: 5.958

View more
  5 in total

Review 1.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Serum beta-endorphin in non-dialysed and haemodialysed patients with chronic renal failure.

Authors:  P Trelewicz; W Grzeszczak; R Drabczyk
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

3.  Limited effects of beta-endorphin compared to loperamide or fentanyl in a neuroendocrine biomarker assay in non-human primates.

Authors:  Eduardo R Butelman; Brian Reed; Brian T Chait; Marek Mandau; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Psychoneuroendocrinology       Date:  2008-01-02       Impact factor: 4.905

Review 4.  Recent advances in the management of pruritus in chronic liver diseases.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

5.  Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch® capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus.

Authors:  Hideki Kozono; Hiroshi Yoshitani; Ryoko Nakano
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-01-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.